Top

Molecular Imaging and Biology

Published in:

01-02-2010 | Research Article

Evaluation of the Radiocobalt-Labeled [MMA-DOTA-Cys⁶¹]-Z_HER2:2395-Cys Affibody Molecule for Targeting of HER2-Expressing Tumors

Authors: Helena Wållberg, Sara Ahlgren, Charles Widström, Anna Orlova

Published in: Molecular Imaging and Biology | Issue 1/2010

Abstract

Purpose

Imaging using positron emission tomography (PET) in the field of nuclear medicine is becoming increasingly important. The aim of this study was to develop a method for labeling of affibody molecules with radiocobalt for PET applications.

Procedures

The human epidermal growth factor receptors type 2 (HER2) binding affibody molecule DOTA-Z₂₃₉₅-C was radiolabeled with ⁵⁷Co (used as a surrogate of ⁵⁵Co). The binding specificity and cellular processing of the labeled compound was studied in vitro followed by in vivo characterization in normal and tumor-bearing mice. Furthermore, a comparative biodistribution study was performed with a ¹¹¹In-labeled counterpart.

Results

DOTA-Z₂₃₉₅-C was successfully labeled with radiocobalt with nearly quantitative yield. The compound displayed good retention on cells over time and high tumor accumulation of radioactivity in animal studies. Imaging studies showed clear visualization of HER2-positive tumors. Furthermore, the radiocobalt label provided better tumor-to-organ ratios than ¹¹¹In.

Conclusions

Radiocobalt is a promising label for affibody molecules for future PET applications.

Tolmachev V, Orlova A, Nilsson FY et al. (2007) Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther 7:555–568CrossRefPubMed

Orlova A, Feldwisch J, Abrahmsén L, Tolmachev V (2007) Update: affibody molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm 22:573–584CrossRefPubMed

Nilsson FY, Tolmachev V (2007) Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel 10:167–175PubMed

Orlova A, Magnusson M, Eriksson TL et al. (2006) Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 66:4339–4348CrossRefPubMed

Masood S, Bui MM (2000) Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 30:259–265PubMed

Simon R, Nocito A, Hubscher T et al. (2001) Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 93:1141–1146CrossRefPubMed

Bast RC Jr, Ravdin P, Hayes DF et al. (2001) 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865–1878PubMed

Molina R, Barak V, van Dalen A et al. (2005) Tumor markers in breast cancer—European Group on Tumor Markers recommendations. Tumour Biol 26:281–293CrossRefPubMed

Tolmachev V, Nilsson FY, Widström C et al. (2006) ¹¹¹In-benzyl-DTPA-Z_HER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 47:846–853PubMed

10.

Orlova A, Tolmachev V, Pehrson R et al. (2007) Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 67:2178–2186CrossRefPubMed

11.

Ahlgren S, Orlova A, Rosik D et al. (2008) Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules. Bioconjug Chem 19:235–243CrossRefPubMed

12.

Tolmachev V, Xu H, Wållberg H et al. (2008) Evaluation of maleimido derivative of CHX-A″ DTPA for site-specific labeling of Affibody molecules. Bioconjug Chem 19:1579–1587CrossRefPubMed

13.

Tran T, Engfeldt T, Orlova A et al. (2007) ^99mTc-maEEE-Z_HER2:342, an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem 18:1956–1964CrossRefPubMed

14.

Ekblad T, Tran T, Orlova A et al. (2008) Development and preclinical characterisation of ^99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging 35(12):2245–2255CrossRefPubMed

15.

Cheng Z, De Jesus OP, Namavari M et al. (2008) Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific ¹⁸F-labeled protein scaffold molecules. J Nucl Med 49:804–813CrossRefPubMed

16.

Kramer-Marek G, Kiesewetter DO, Martiniova L et al. (2008) [¹⁸F]FBEM-Z_HER2:342-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 35:1008–1018CrossRefPubMed

17.

Lundqvist H, Tolmachev V (2002) Targeting peptides and positron emission tomography. Biopolymers 66:381–392CrossRefPubMed

18.

Jansen HM, Pruim J, van der Vliet AM et al. (1994) Visualization of damaged brain tissue after ischemic stroke with cobalt-55 positron emission tomography. J Nucl Med 35:456–460PubMed

19.

Jansen HM, Willemsen AC, Sinnige LG et al. (1995) Cobalt-55 positron emission tomography in relapsing-progressive multiple sclerosis. J Neurol Sci 132:139–145CrossRefPubMed

20.

Goethals P, Volkaert A, Vandewielle C et al. (2000) ⁵⁵Co-EDTA for renal imaging using positron emission tomography (PET): a feasibility study. Nucl Med Biol 27:77–81CrossRefPubMed

21.

Heppeler A, André JP, Buschmann I et al. (2008) Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumor targeting. Chemistry 14:3026–3034CrossRefPubMed

22.

Persson M, Tolmachev V, Andersson K et al. (2005) [¹⁷⁷Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging 32:1457–1462CrossRefPubMed

23.

Milenic DE, Garmestani K, Brady ED et al. (2004) Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 10:7834–7841CrossRefPubMed

24.

Lundberg E, Höidén-Guthenberg I, Larsson B et al. (2007) Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. J Immunol Methods 319:53–63CrossRefPubMed

25.

Lindmo T, Boven E, Cuttitta F et al. (1984) Determination of the immunoractive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72:77–89CrossRefPubMed

26.

Orlova A, Rosik D, Sandström M et al. (2007) Evaluation of [^111/114mIn]CHX-A''-DTPA-Z_HER2:342, an affibody ligand conjugate for targeting of HER2-expressing malignant tumors. Q J Nucl Med Mol Imaging 51:314–323PubMed

27.

Orlova A, Tran T, Widström C et al. (2007) Pre-clinical evaluation of [¹¹¹In]-benzyl-DOTA-Z_HER2:342, a potential agent for imaging of HER2 expression in malignant tumors. Int J Mol Med 20:397–404PubMed

28.

Ginj M, Zhang H, Waser B et al. (2006) Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A 103:16436–16441CrossRefPubMed

29.

Garrison JC, Rold TL, Sieckman GL et al. (2007) In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using ⁶⁴Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med 48:1327–1337CrossRefPubMed

30.

Prasanphanich AF, Nanda PK, Rold TL et al. (2007) [⁶⁴Cu-NOTA-8-Aoc-BBN(7-14)NH₂] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A 104:12462–12467CrossRefPubMed

Title: Evaluation of the Radiocobalt-Labeled [MMA-DOTA-Cys61]-ZHER2:2395-Cys Affibody Molecule for Targeting of HER2-Expressing Tumors
Authors: Helena Wållberg
Sara Ahlgren
Charles Widström
Anna Orlova
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: Molecular Imaging and Biology / Issue 1/2010
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-009-0238-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evaluation of the Radiocobalt-Labeled [MMA-DOTA-Cys⁶¹]-Z_HER2:2395-Cys Affibody Molecule for Targeting of HER2-Expressing Tumors

Abstract

Purpose

Procedures

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Procedures

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Modification of Aminosilanized Superparamagnetic Nanoparticles: Feasibility of Multimodal Detection Using 3T MRI, Small Animal PET, and Fluorescence Imaging

Feasibility of Whole-Body Functional Mouse Imaging Using Helical Pinhole SPECT

The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT

High-Affinity αvβ3 Integrin Targeted Optical Probe as a New Imaging Biomarker for Early Atherosclerosis: Initial Studies in Watanabe Rabbits

Achieving Greater Synergy

Comparison of Gene-Transfer Efficiency in Human Embryonic Stem Cells